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Bovine placental lactogen (bPL) exhibited antimitogenie differentiation-promoting biological ctivity in 3T3-F442A preadipoeytes. Competitive 
binding studies and affinity labelling r~vealed bPL activity to be mediated through asomatogenic type of receptor that r~ogniz~ human growth 
hormone (hGH) and bovine GH, but not ovine prolaetin or human PL. The bioaetivity ofbPL was sixfold lower thaa that of hGH d~pit¢ that 
bPL is binding to the somatogcnic r¢~ptors with fivefold higher affinity. This diserc~-'ancy may result from the relatively ow ability of bPL to 
ind.e¢ post.,'eeeptoral effects such a~ receptor dimerization. 
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1. INTRODUCTION 
Placental actogens (PLs) are polypeptide hormones 
produced and secreted by mammalian placentas 
throughout pregnancy. Human, rodent, coin© and bo- 
vine PLs have been isolated and sequenced [1]. Their 
structure is similar to that of related pituitary 
hormones, such as prolaetins (PRLs) and growth 
hormones (GHs). Bovine PL (bPL) has been purified 
from term placental homogenates [2] and from isolated 
secretory granules obtained from binucleate cells of the 
fetal cotyledon [3]. The native 31-33 kDa protein has 
at least five isoelectric variants which are the result of 
heterogeneity of the attached oligosaecharides a  well as 
other, as yet unidentified modifications. The gone for 
bPL has been cloned and expressed with high efficiency 
in E. coil, and the recombinant bPL was purified to 
homogeneity [4]. The predicted mature bPL has 200 
residues and the primary sequence has 50% and 23% 
homology to bPRL and bGH, respectively [4]. Deglyco- 
sylafion of native bPL has no effect on PRL-like mitt- 
genie activity in the Nb2 lymphoma cell proliferation 
assay and only slightly reduces its binding to liver bGH 
receptors [5]. It has been suggested that bPL or ovine 
PL (oPL) may mimic the action of either GH [6] or PRL 
[7], though evidence that the resultant activity is 
transduced through respective OH or PRL receptors 
was not provided. Other studies have suggested a dis- 
tinct and unique PL receptor in fetal and maternal sheep 
livers [8,9]. We recently reported [10] this uaique recep- 
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tor for bPL in endometrium from mid-pregnant heifers. 
Thus, the question of whether the biological activity of 
bPL is mediated through several distinct receptors has 
yet to be resolved. In the present study we attempted to 
answer this question, using 3T3-F442A rat preadi- 
pocytes as a model. These ¢¢11s possess a well-defined 
somatogenic receptor that recognizes not only hGH, 
but other GHs as well [11,12]. It has been reported that 
hGH is required for differentiation of these cells to 
adipoeytes [13] and that under defined conditions, hGH 
exhibits antimitogenic activity [14]. 
2. MATERIALS AND METHODS 
2.1. Materials 
Recombinant bPL was obtained from Monsanto Co. (St. Louis, 
MO, lISA) prepared as d~cri.bed previously [1~. Recombinant bo- 
vine and human growth ormones were obtained from Biotechnology 
General lag. (Rehovot, Israel), ~trrier-free Nallnl] was purchased 
from the New England Nuclear Corp. (Boston, MA, USA) and a 20K 
hGH variant, hPL and bPRL from the National Institute of Health 
(laethesda, MD, USA). Molecular weiBht (Mr) markers for gel electro- 
phorcJis, FL~ber's, RPMI-1640 and DME media nd bovine scnan 
albumin (BSA, RIA grade) were obtained from Sigma Chemical Corp. 
(St. Louis, MO, USA). Sodium dodeeyl sulfate imlyacrylamid¢ gel 
¢leetrophoresis (SDS-PAGE) reagents and Protein Afaay Kit were 
purchased from Bit-Rod Laboratories (Richmond, CA, USA) and 
disaeeinimidyl sabemte (DSS) from Pierce Chcaniml Co. (Rogkford, 
MA, USA). LactoBen-free horse ~rum, fetal calf scram (FCS) and 
calf serum (CS) were obtained from Binlab Co. (Jem~lcm, Israel) and 
Bet-Haemek Co. (Bet-Haemek, Israel). 3T3-F442A preadipocyt~ de- 
veloped in the laboratory of Dr. H. Green [16] (Boston, MA, USA), 
were obtained from Dr. J. Schwartz (Ann Arbor, MI, USA). All other 
chemicals were of analytical grade. 
2.2. Binding assays 
3T3-F442A preadiImeyte~ were "~'de.,d insi~-well platen at 80,000-- 
100,000 cells/well and cultured in DME m~ium supplemented with 
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10% CS for 12-14 days until full confluenc~ was achieved. The wells 
were then washed with 1 ml phosphate-buffered saline (PBS) followed 
by 0.5 ml PBS containing 1,% BSA. One ml PBS containing 1% BSA 
was then added and the plates were transferred to 4°C. After 30 rain, 
the tracer ([ml]hGH or [~2SI]bPL) with or without untabelled hormone 
was added and the incubation was continued for 16 h. Wells were then 
washed (3 x 1 ml) with ice-cold PBS, and 1 ml of 10 mM NaOH was 
added. Four hours later, the well contents were transferred to Eppen- 
doff tuh~s and counted in a gamma counter. Iodination of hGH and 
bPL was carried out as described previously [17],. 
2.3, Affinity labelling 
3T3-F442A prcadipocytes were seeded in 1S-cm diameter dishes 
and cultured as described above. After washing, 10 ml of cold PBS 
containing 1% BSA and radiolabelled bl)L or hGH ( -2 x 10 ~ cpm, 
~I0 ng) was added and the cells were incubated at 4"C. For a deter- 
ruination of non-specific binding, 40 #g of either bPL or hGH were 
added. After 16 h of incubation, DSS was added to a final concentra- 
tion of 0.5 mM and the incubation was continued for 25 rain. The 
reaction was then quenched by addition of 0,1 ml 5 M Tris-HCl, pH 
7.5. The dishes were washed thoroughly with cold PrtS (3 × 5 ml) and 
cells were removed with a rubber policeman and collected to Eppcn- 
doff tubes. Following addition of 250/~1 of sample buffer containing 
50 mM DTT, the cells were briefly sonicated, boiled for 5 rain and 
subjected to SDS-PAGE [18]. The gels were dried and autoradiogra- 
phed at -70"C using Agfa RP2 film. 
2.4. 3T3.F442A pread/pac.vte bioassa), 
3T3-F442A preadipocytes were seeded at high confluence in24-well 
plates in medium containing 10% CS. After 24 h the cells were trans- 
ferred to a serum-free medium containing supplemental proteins [14] 
and increasing concentrations of various tested homaones (0.09-25.0 
ng/ml) and cultured for five days. Following incubation, the medium 
was changed to 4% FCS and DNA synthesis was determined 20h later 
by a 2-h pulse of 2 ~Ci/ml [~H]thymidine. 
2.5. Nb2 lymphoma cell culture 
Culture of the Nb:.IIC lymphoma ~11 lin~, synchronization f 
Nb2-1 IC c~lls in the GdGt phase and monitoring ofcell proliferation 
were carried out as described previously [19]. 
3. RESULTS 
3.1. Binding studies 
Results of the competitive binding studies to intact 
3T3-F442A preadipocytes indicated that binding of ei- 
ther [~25I]hGH or [~2~I]bPL to be competed away by 
either of the respective unlabelled hormones (Fig. 1). 
Bovine GH competed with both tracers similarly, while 
oPRL dld not compete at all. However, the affinities of 
the bPL, hGH and bGH were not identical. Using, 
respectively, the radiolabelled bPL or hGH as tracers, 
the corresponding IC50 values for bPL, hGH and bGH 
(in rig/tube) were: 6, 32, 18 and 1.2, 7, 15. These results 
were confirmed using homologous binding assays with 
[~2SI]bPL or [~2~I]hGH as tracers. Scatchard analyses 
revealed a single receptor population for both eases. 
The respective Ka values for bPL and hGH were 64 and 
328 pM while the Bm,~ values (in fmol/well) were 17.8 
and 17.7. Although the precise cell number could not be 
determined for each well, an average number observed 
in other experiments for confluent wells was 1.34 × 106. 
Based on this, the average number of receptors/well was 
-8,000, in agreement with others [16]. 
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Fig. I. Competition of unlabelled hOH (A), bPL (o), bGH (¢~) and 
oPRL (v) with the binding of [l-'Sl]bPL (A) and [t~Sl]hGH (B, average 
of two experiments). The full lines were calculated using the Sigma plot 
curve fitting program and the symbols represent actual results. 
3.2. Affinity labelling 
Affinity labelling of the receptors in intact 3T3- 
F442A cells was carried out in the presence of [~2~I]hGH 
and [~:5I]bPL. Both tracers gave similar electrophoretic 
profiles and labelling was prevented by both exce3s un- 
labelled hGH or bPL (Fig. 2). The main labelled band 
had an Mr of 130 kDa, indicating the M, of the receptor 
to be ~ 108 kDa. Other bands having the respective Mr 
values of 109, 89, 83 and 43 were observed in both 
tracers, hinting that they may have resulted from partial 
proteolysis, which is independent of tracer type. 
3.3. Biotogical activity 
The antimitogenic a tivities of bPL, hGH, bGH and 
other related hormones determined in four experiments 
were compiled and averaged and are presented in Fig. 
3. Since the absolute values of ['~H]TdR incorporation 
and the maximal inhibition varied in different experi- 
ments, the final results were normalized, by assuming 
that maximal inhibition (residual activity = 0) was 
achieved in the presence of 25 ng/ml ofhGH. The values 
of treatments obtained in the absence of the assayed 
hormones were taken as 100. Each experimental result 
obtained in the presence of a different dose of each 
hormone was normalized and these values were then 
averaged and presented as mean +_ S.E.M. 
The IC~o values calculated from the results shown in 
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Fig. 2. Affinity labellin~ of lact0gen receptors in intact 3T3-F442A 
preadipocytes, Intact cells wet= incubated with [t=SllhGH (lanes 1-3) 
or [t2q]bPL (lanes 4--6) in th~ absence (lanes I and 4) or presence (lanes 
2 and 6) of40/zg unlabclled hGH or unlabelled bPL (lanes 3 and 5), 
After cross-linking with DSS, the cells were washed, subjected to 
SDS-PAGE (7.S%)and autoradiographed. 
Fig. 3 indicated the strongest antimitogenic a tivity to 
be exhibited by hGH (IC~o = 0.13 ng/well), while bE}H, 
bPL and the 20K variant of hE}H were three- to sixfold 
less potent. Their respective Its0 values were (in ng/ 
well): 0.33, 0.60 and 0.72. Human PL and oPRL were 
only slightly or not at all active. 
In order to evaluate the possible reason for the differ- 
ences in their bioactivities, various hormones were as- 
sayed simultaneously b the Nb, lymphoma cell bioas- 
say in which the bioactivity is transmitted through a 
lactogcnic type of receptor [19]. Human (3H, bPL, 
oPRL and the 20K variant of  hGH were equally potent, 
while the activity of hPL was fourfold weaker. Bovine 
GH was not tested since it is inactive in this bioassay 
[19]. 
4. DISCUSSION 
Our results clearly suggest the biological activity of 
bPL in 3T3-F442A preadipocytes to be mediated by its 
interaction with the growth hormone (somatogenic) re- 
ceptor. This conclusion is based on the following exper- 
imental findings: (a) binding expe.riments revealed mu- 
tual competition, (b) only a single population of recep- 
tors was detected and the overall number of binding 
sites for hE}H and bPL per cell was almost identical, (c) 
the Mr of the receptor or its partially degraded frag- 
ments was identical for both tracers and matched previ- 
ously reported values [l 1,12]. Recent in vivo experi- 
ments in which recombinant bPL stimulated the growth 
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Fig. 3. The antimitogenie effect ofbPL (o), hGH (A), bGH (o), oPRL 
(,), 20K hGH (o) and hPL (1) in 3T3.F442A preadipocytes. After 
se~ing the cells were transfcrr~ to a s~rum-fr~ medium containing 
supplemental proteins (14) and increasing concentrations of bPL or 
other hormones and cultured for five days. Then the medium was 
changed to 4% FCS and DNA synthesis was demrmined 20 h later by 
a 2 h pulse of 2/zCi/ml [~H]thymidin¢, Results represent the normal. 
ized mean __ S.E,M. of four ¢xpcrhnents. 
of rats in a manner Sitnilar to bGH [15] further substan- 
tiate our conclusion. 
Surprisingly however, the biological activity of bPL 
in 3T3-F442A preadipocytes was sixfold lower than 
that of hGH, despite bPL affinity is fivefold higher for 
the receptors. This lower biological activity could not 
be attributed to improper refolding of the recombinant 
bPL, since in the Nb.~ lymphoma cell bioassay, its activ- 
ity was equal to hGH and its CD spectrum indicated 
-60% of an 0c-helix structure, as expected from the 
properly folded hormone [21]. This paradoxical finding 
can be explained, however, by recent reports showing 
that hGH has two nonsymmetrical binding sites and 
acts as a cross-linker to form a complex with two mole. 
cules of the hGH receptor extracellular domain [22,23]. 
Structural homology between bPL and hGH hints at the 
possibility that bPL and other related hormones, such 
as PRLs, act in a similar manner. In recent experiments 
we have found that bPL can form a 1:2 complex with 
the cloned extracellular part of the bovine liver GH 
receptor, but its affinity for the binding of the second 
receptor molecule is lower than that of hGH (Vasdi, 
Sakal and Gertler, unpublished ata). We have also 
suggested that d~,e.rization of the lactogcn receptor, 
which is structurally similar to the somatogenic receptor 
is the first event leading to the initiation of the mitogenic 
signal in Nb.~ lymphoma cells [24]. Thus binding, that 
is less effective in inducing dimerization may lead to 
diminished biological activity, despite higher affinity for 
the respective rec, ptor. The discrepancy in the relative 
biological activities of bPL and hGH in the 3T3-F442A 
preadipocytes and Nba cell bioassay may therefore re- 
sult from minor structural differenc¢s in the binding 
domains of the hormones. The differences in the IC~0 
values found in the bioassay and the Ads calculated 
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from the binding experiments also indicate that partial 
occupation of the receptors is sufficient o exhibit max- 
imal biological effect. 
In summary it is evident that bPL (and prabably 
other PLs as well) are extremely versatile hormones, 
capable of transducing diverse biological signals 
through a minimum of two subfamilies (GH and PRL) 
of receptors. Additional biological activities, mostly un- 
known to date, may be transduced through an addi- 
tional, unique r~eptor ofbPL [10,25] that does not bind 
GHs and PRLs. Throughout pregnancy, bPL appears 
not only in the fetal but also in the maternal circulation, 
raising the as yet unanswered question of its in rive 
mode of activity. 
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